Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Analysts at Zacks Research boosted their Q4 2024 EPS estimates for Sarepta Therapeutics in a report released on Monday, February 3rd. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of $1.24 per share for the quarter, up from their previous estimate of $1.00. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.55 per share. Zacks Research also issued estimates for Sarepta Therapeutics' Q2 2025 earnings at $2.65 EPS, Q3 2025 earnings at $2.61 EPS, Q4 2025 earnings at $2.88 EPS, FY2025 earnings at $10.04 EPS, Q1 2026 earnings at $3.06 EPS, Q2 2026 earnings at $3.58 EPS, Q3 2026 earnings at $3.56 EPS, Q4 2026 earnings at $3.60 EPS and FY2026 earnings at $13.80 EPS.
A number of other equities analysts have also recently weighed in on the company. Evercore ISI dropped their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. Jefferies Financial Group began coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They set a "buy" rating and a $165.00 target price on the stock. HC Wainwright reaffirmed a "sell" rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, January 30th. Cantor Fitzgerald raised Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and upped their price target for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, Robert W. Baird decreased their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics has an average rating of "Moderate Buy" and an average target price of $178.71.
Check Out Our Latest Analysis on Sarepta Therapeutics
Sarepta Therapeutics Price Performance
Shares of SRPT traded down $0.29 during trading hours on Thursday, hitting $111.82. 881,445 shares of the company were exchanged, compared to its average volume of 847,020. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company has a market capitalization of $10.68 billion, a PE ratio of 89.46 and a beta of 0.75. The firm has a fifty day simple moving average of $121.12 and a 200-day simple moving average of $125.96. Sarepta Therapeutics has a one year low of $102.15 and a one year high of $173.25.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the business. CIBC Asset Management Inc boosted its holdings in shares of Sarepta Therapeutics by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company's stock valued at $339,000 after purchasing an additional 86 shares in the last quarter. Louisiana State Employees Retirement System grew its position in Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock valued at $3,222,000 after acquiring an additional 100 shares during the last quarter. Manchester Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 110 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Sarepta Therapeutics by 36.0% in the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock worth $63,000 after acquiring an additional 138 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. grew its holdings in shares of Sarepta Therapeutics by 3.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company's stock valued at $557,000 after purchasing an additional 145 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.
Insider Activity at Sarepta Therapeutics
In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company's stock, valued at $738,234. This represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.
About Sarepta Therapeutics
(
Get Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Featured Stories
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
